Sorafenib shows success in advanced differentiated thyroid cancer patients

April 25, 2014 by Steve Graff, University of Pennsylvania School of Medicine

(Medical Xpress)—The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania published in the journal Lancet. This is the first effective treatment for thyroid cancer patients who progress following standard treatments.

Preliminary results of this randomized phase III trial were presented at a plenary session during the American Society of Clinical Oncology's annual meeting in 2013.

Based on these data, sorafenib was approved by the U.S. Food and Drug Administration (FDA) in November 2013 for patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to treatment. These patients previously had limited approved treatment options.

Thyroid cancer is highly curable through surgery and , but about 10 percent of the 60,000 patients who are diagnosed with the disease each year fail to respond to standard therapies, with tumors eventually appearing in the lungs, lymph nodes, bones and other sites. The only other drug for advanced , doxorubicin, which was approved in 1974, is not used because it is highly toxic and is not effective.

"Until we began using sorafenib, we had no effective treatment options for these patients who suffered due to progression of their disease," said Marcia S. Brose, MD, PhD, an assistant professor in the department of Otorhinolaryngology: Head and Neck Surgery in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, who led the study, which is known as DECISION. "Now, we can give patients hope – a breakthrough medication that can stop the progression of the disease for an average of five months. This trial is the first step in a promising series of clinical trials to identify new drugs that are shifting the horizon for patients with advanced differentiated thyroid cancer."

Of the 417 metastatic thyroid cancer patients studied in the multicenter, international trial, 207 were randomized to take sorafenib, an oral drug, and 210 to a placebo arm. The study met its primary endpoint showing that among patients taking sorafenib, median progression-free survival was 10.8 months, compared to 5.8 months among the placebo group.

Twelve percent of patients experienced tumor shrinkage in the sorafenib arm, compared to 0.5 percent of patients taking a placebo. Importantly, the therapy also appeared to thwart disease progression even among many of those whose tumors did not achieve partial response: 42 percent of patients who took sorafenib had stable disease after six months, compared to 33 percent of those in the placebo group.

The most common adverse events observed among patients taking sorafenib included hand-foot skin reaction, diarrhea, alopecia, rash, fatigue, weight loss and hypertension, all of which are manageable and consistent with findings from previous trials of the drug for its approved indications.

The study also showed that sorafenib improves progression free survival across all subgroups and in patients irrespective of the BRAF or RAS mutations—which are common in patients with radioactive iodine refractory differentiated thyroid cancer. Thus, those mutations are not predictive biomarkers for cancers treated with sorafenib.

"Sorafenib is the first effective and well tolerated drug to improve the outcomes for patients with radioactive iodine refractory and progressing differentiated thyroid cancer, and as such represents the new standard of care for that suffer from this this disease," said Brose.

Explore further: Targeted therapy sorafenib shows success in advanced differentiated thyroid cancer patients

Related Stories

Targeted therapy sorafenib shows success in advanced differentiated thyroid cancer patients

June 2, 2013
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher ...

Researchers unveil findings on two new weapons against thyroid cancer

September 28, 2013
For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers ...

Nexavar approval expanded for common thyroid cancer

November 24, 2013
(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

September 29, 2012
Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO ...

Recurrent but rare mutations might underlie cancer growth

February 26, 2014
A potential new gene mutation that might drive lung cancer development and growth has been identified by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.